Articles On Patrys (ASX:PAB)

ASX200 hits record high driven by US Fed interest rate cut Mining stocks surge as iron ore prices rebound ALS shares drop 10pc, Monadelphous rises on new contracts   The ASX200 hit yet another record high today, boosted by the first inte...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX up as earnings season rolls on; Origin down 10pc, Telstra up 3pc Australia’s unemployment rate edged up to 4.2pc from 4.1pc Iron ore futures dropped below US$94 per ton   The ASX edged slightly higher by 0.1% on Thursday, boosted by a...

ASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps   Aussie stocks have closed higher on Monday as IT and retail stocks added strength to sentiment. The S&P/ASX200 closed higher, gaining 36.00 points...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Good morning, and welcome to Stockhead’s Top 10 at shortly-after-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the t...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The ASX200 closed +0.5% higher on Tuesday on the back of a big lift in the Mining sector.  Lithium stocks led, with IGO (ASX:IGO) and Pilbara (ASX:PLS) gaining around 3%.  Iron ore miners  rallied after the Nymex CFR China, 62% Fe price swu...

Patrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. The therapeutic antibody developme...

Patrys’ deoxymabs data on vasculitis disease presented Next Science’s BLASTX data published   Patrys’ deoxymabs data presented Patrys (ASX:PAB) jumped 12% this morning after announcing that new data from preclinical studies using PAT-DX1...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

  Local markets started slow before ripping into an all-time intraday high  10 of 11 sectors higher, benchmark closes 0.50pc up Small Caps led by Motio, Cue Energy and Sierra Rutile   Some strong earnings on the last day of February and...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

The ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Times among the lithium players, it’s been a total snoozefest Rubix Resources (ASX:RB6) takes bragging rights with a 41.6% hike for the day  ...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Patry receives positive toxicology reports on PAT-DX1 Immutep says triple combination trial of Efti shows it is well tolerated Clarity Pharma is now advancing to cohort 2   Patrys receives positive report Therapeutic antibody development...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX sinks to -0.4% before slogging its way back to -0.22% for the day. Tech stocks were all over the shop but came out on top with +1.2%. Wildcat (ASX:WC8) was King of the Small Caps, adding 34.5% on no fresh news.   After sinking as low...

ASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today, adding 0.5% on an otherwise fairly moribund day Voltaic Strategic Resources climbs 188% on pre-assay lithium results at Ti Tree   The ASX h...

The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stable commodity prices and mining stocks saw the ASX break its seven-week losing streak. The ASX 200 is up 2 per cent this year so far after adding 55 points today. All but one of the 11 sectors were in the green, with materials lead...

ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So...

As the first quarter of this calendar year wraps up, Sayona Mining (SYA) and Piedmont Lithium (PLL) have restarted the North American lithium project in Quebec, Canada. Re-start operations were first announced in 2021 and since then, the...

Patrys (PAB) shares are slumping on Friday after the company flagged delays over the phase one clinical trial of its PAT-DX1 compound PAB CEO and Managing Director James Campbell says it is “disappointing” to push back the trial for its...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic le...

ShareCafeASX falls 1.4% to three-month low by Peter Milios   At the closing bell, the S&P/ASX 200 was 1.4 per cent lower at 7,008.9, a three-month low. The fall was mainly due to concerns about a financial crisis after the collapse of U...

Patrys (PAB) claims a recent pre-clinical study of its PAT-DX3 drug shows the product could treat cancer through “synthetic lethality” strategies The company says its drug platform is designed to cause DNA damage to certain tumours to ul...

ShareCafeASX down 1.91% at noon to lowest point since Jan by Peter Milios   Earlier today, the S&P/ASX 200 stock index of Australia experienced a decline of 2.1 per cent and hit a new low of 6956.7, which is close to its lowest point of...